Hot Investor Mandate 4: China-Based Fund Opportunistically Invests in Medtech, Biotech, Healthcare IT and Diagnostics

9 Mar

A venture capital firm based in Shanghai, China, is managing one fund with committed capital of $140 million. The firm typically makes equity investment into life science companies at various stages. The investment size generally ranges from $10 million to $15 million over the life of an investment. The firm seeks to make 3-5 allocations in the next year. The firm focuses on companies that are based in China and the US.

The firm is currently looking for new investment opportunities in Biotechnology R&D, Therapeutics & Diagnostics, Pharmaceuticals, Medical Devices and Healthcare IT spaces. The firm is very opportunistic in terms of subsectors and indications. The firm is interested in in-licensing products or technologies for development from companies outside of China, such as US-based companies. The firm also seeks to invest in orphan drugs. Prior investments have included medical device companies, diagnostics companies, CRO and distributors. The firm will consider companies in all stages, depending on the opportunity.

The firm seeks to invest in both private and public companies. The firm has no specific requirements for companies’ management team, revenue or EBITDA.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: